Wall St futures steady as Fed cut hopes remain firm; PCE inflation on tap
Investing.com -- InflaRx (NASDAQ:IFRX) stock surged 60% after the biopharmaceutical company reported positive Phase 2a data for its oral C5aR inhibitor INF904 in treating Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU).
The company’s Phase 2a basket study showed promising efficacy results across both indications, with particularly strong responses in HS patients. Over a 4-week treatment period, InflaRx observed rapid and clinically meaningful reductions in abscesses, nodules, and draining tunnels, along with substantial pain relief for HS patients.
For CSU patients, the drug demonstrated substantial reductions in the 7-day Urticaria Activity Score (UAS7), especially in those with severe disease. The 60mg twice-daily dose showed the strongest results, with a UAS7 change from baseline of -13.7 points at Week 4, which the company believes exceeds historical placebo levels.
"These data support INF904 as a potentially transformational and best-in-class immunomodulatory agent," the company stated, highlighting the drug’s strong safety profile with no serious adverse events reported in either indication.
The study evaluated multiple dosing regimens over 4 weeks with an additional 4-week follow-up period. Notably, clinical responses continued to deepen even after treatment ended, suggesting potential long-term benefits from the therapy.
InflaRx is prioritizing Phase 2b development for INF904 in HS, with plans to initiate trials in 2026. The company also indicated it is in active discussions with potential collaborators to expedite development across multiple inflammatory disorders.
The company believes the addressable market for INF904 could exceed $1 billion in both indications, positioning the drug as what it describes as a "pipeline-in-a-product" with broad therapeutic potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.